Table 1.
Description of the Included Studies
| Study | Sample Size (male/female) | Country | Ethnicity |
Age
(SD) |
Setting | Diagnostic Criteria | Patient Type | Medication | Duration of Treatment | Outcome Measure | HTR1A SNP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Crisafulli et al., 2012 | 221 (126/95) |
Korea | Asian | 38.01 (12.67) |
In-patients | DSM-IV | Not any particular restriction | RIS, OLZ, QEP, AMI and others (All APDs are not identified) | 37.64±1S6.76 days from admission to discharge | PANSS | rs10042486, rs6295, rs878567, rs1423691 |
| Drago et al., 2013 | 96 (51/45) |
German, Yugoslavia, Turkey, Other | Caucasian | 34.28 (11.29) |
In-patients | DSM-IV | Acute | HPD | 4W | PANSS | rs6295, rs878567, rs1423691, rs10085024 |
| Gupta et al., 2012 | 371 (224/147) |
India | South Indian | 29.63 (8.63) |
In and out- patients | DSM-IV | Most of them are of chronic patients | RIS, OLZ, CLZ, ZIP, QEP, ARI, AMI | 3M | CGI-I | rs6295, rs34118353, rs878567, rs1423691 |
| Ikeda et al., 2008 | 120 (58/62) |
Japan | Asian | 31.2 (8.7) |
In and out- patients | DSM-IV-TR | First-episode, neuroleptic- naïve DUP < 5 y |
RIS | 8W | PANSS | rs6295 |
| Mossner et al., 2009 | 68 (44/24) |
German | Caucasian | 31.7 | NR | ICD-10 | First-episode | RIS, HPD | 4W | PANSS | rs6295 |
| Reynolds et al., 2006 | 63 (45/18) |
Spain | Caucasian | 25.1 (6.5) |
In and out- patients | Drug-naive patients with first-episode psychosis | Drug-naive patients with first-episode psychosis | RIS, OLZ, QEP, HPD, ZIP, AMI | 3M | PANSS | rs6295 |
| Sumiyoshi et al., 2010 | 30 (11/19) |
Japan | Asian | 31.6 (11.0) |
Out-patients | DSM-IV-TR | Acute | OLZ, PER | 3M | SAPS, SANS | rs6295 |
| Takekita et al., 2015 | 100 (43/57) |
Japan | Asian | 44.1 (16.2) |
In and out- patients | DSM-IV-TR | Acute | PER, ARI | 12W | PANSS | rs1364043, rs878567, rs6295, rs10042486 |
| Tang et al., 2014 | 82 (45/37) |
Chinese | Asian | 25.8 (7.1) |
In-patients | DSM-IV | First psychotic episode | Baseline：CPZ, RIS, CLZ, FLU endpoint：CLZ, CPZ, RIS |
10W | PANSS and PANSS 5 factors | rs6295 |
| Wang et al., 2008 | 130 (43/87) |
China | Asian | 30.35 (11.33) |
NR | DSM-IV | - Not treatment resistance - SGAs-naïve - Not APDs administration for 4W |
RIS | 8W | PANSS | rs6295 |
Abbreviations: AMI, amisulpride; APD, antipsychotic drug; ARI, aripiprazole; CGI-I, clinical global impression of improvement; CLZ, clozapine; CPZ, chlorpromazine; DUP, duration of untreated psychosis; FLU, fluphenazine; HPD, haloperidol; NR, not reported; OLZ, olanzapine; PANSS, Positive and Negative Syndrome Scale; PER, perospirone; QEP, quetiapine; RCT, randomized clinical trial; RIS, risperidone; SAPS, scale for assessment of positive symptoms; SANS, scale for the assessment of negative symptoms; SGA, second-generation antipsychotic; SNP, single nucleotide polymorphism; ZIP, ziprasidone.